Aghetto - THE NEW SYRINGE USABLE WITH ONLY ONE HAND
Syringes currently on the market require two hands to use
Aghetto S.r.l. is a start up owner of the technology for an innovative syringe, designed to be used with only one hand and to reduce the risk of needle-stick injuries.
Aghetto syringe needs only one hand to detach the cap from the needle and the needle from the syringe, the other hand is free and can be used for other tasks (e.g.holding a medicine vial, a cotton ball, a venous cannula , other medical tools or - in veterinary medicine - to keep the animal still)
The Aghetto syringe needs only one hand to detach the cap from the needle and the needle from the body of syringe. The other hand is free and can be used for other tasks (e.g. holding a medication’s vial or a venous/arterious cannula, disinfecting, or - in veterinary medicine - to hold still the pet).
The Aghetto syringe is easy to use (just turn a tiny wheel) and to produce (just add a tiny wheel to the common syringe during the assembly process).
It is an international patent (Europe, China, USA, Canada, Russia, Brazil, Australia, Israel, South Korea, Japan, India, Hong Kong, South Africa and other countries).
We are available to sell or license the patent.
Needle stick injuries - which are a serious problem within health care systems worldwide - can transmit over 20 blood-born pathogens and infections (HIV, HBV, HCV, Malaria, Ebola and others).
Related News
-
News Understanding the Benefits and Advances of Cleanroom Technology
In an industry where precision and sterility are crucial concerns, cleanrooms play a vital role in maintaining the integrity of pharmaceutical products like drugs, vaccines, and other medical products. So, what is a cleanroom?
-
News AbbVie secures GBP£1.2 billion deal for Gilgamesh’s psychedelic programme
AbbVie has penned a significant agreement to acquire the bretisilocin programme from Gilgamesh Pharmaceuticals for up to £1.2 billion, marking a bold step in the pharmaceutical giant's quest to develop treatments for psychiatric disorders. -
News Gates Foundation commits US$2.5 billion to women’s health research
The Bill & Melinda Gates Foundation has announced a substantial US$2.5 billion commitment to accelerate research and development focused exclusively on women's health through 2030.
-
News Mid-year review: notable FDA drug approvals of 2025
As we fly past the halfway point of 2025, the pharmaceutical landscape reliably continues to evolve with innovative therapies addressing critical medical needs. The FDA has already approved 17 groundbreaking medications this year, each representin... -
News US FDA announces new priority vouchers for accelerated review times
The US FDA announced a new priority program for drug developers – the Commissioner’s National Priority Voucher (CNPV) program aims to enhance the health interests of the US by allowing drug developers to redeem a voucher, shortening th... -
News Google-backed start-up raises US$600 million to support AI drug discovery and design
London-based Isomorphic Labs, an AI-driven drug design and development start-up backed by Google’s AI research lab DeepMind, has raised US$600 million in its first external funding round by Thrive Capital. The funding will provide further power t... -
News AstraZeneca to invest US$2.5 billion in Beijing R&D centre
Amid investigations of former AstraZeneca China head Leon Wang in 2024, AstraZeneca have outlined plans to establish its sixth global strategic R&D centre in China. Their aim is to further advance life sciences in China with major research and manufact... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience.